Co-develop anti-L1 monoclonal antibody therapeutic for treating cancer

Published: 2007-12-05 06:56:00

Updated: 2007-12-05 06:56:00

Celltrion Inc. and German biotech company MediGene AG signed a binding memorandum of understanding for the co-development and commercialization of an anti-L1 monoclonal antibody (anti-L1 MAb) for the treatment of cancer in humans covering major cancer indications, Celltrion officials said on Nove...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK